BACKGROUND: Erdheim-Chester disease (ECD) is a rare histiocytic neoplasm characterized by recurrent alterations in the MAPK (mitogen-activating protein kinase) pathway. The existing literature about the neuro-oncological spectrum of ECD is limited. METHODS: We present retrospective clinical, radiographic, pathologic, molecular, and treatment data from 30 patients with ECD neurohistiocytic involvement treated at a tertiary center. RESULTS: Median age was 52 years (range, 7-77), and 20 (67%) patients were male. Presenting symptoms included ataxia in 19 patients (63%), dysarthria in 14 (47%), diabetes insipidus in 12 (40%), cognitive impairment in 10 (33%), and bulbar affect in 9 (30%). Neurosurgical biopsy specimens in 8 patients demonstrated varied morphologic findings often uncharacteristic of typical ECD lesions. Molecular analysis revealed mutations in BRAF (18 patients), MAP2K1 (5), RAS isoforms (2), and 2 fusions involving BRAF and ALK. Conventional therapies (corticosteroids, immunosuppressants, interferon-alpha [IFN-α], cytotoxic chemotherapy) led to partial radiographic response in 8/40 patients (20%) by MRI with no complete responses, partial metabolic response in 4/16 (25%), and complete metabolic response in 1/16 (6%) by 18F-fluorodeoxyglucose (FDG)-PET scan. In comparison, targeted (kinase inhibitor) therapies yielded partial radiographic response in 10/27 (37%) and complete radiographic response in 14/27 (52%) by MRI, and partial metabolic response in 6/25 (24%) and complete metabolic response in 17/25 (68%) by FDG-PET scan. CONCLUSIONS: These data highlight underrecognized symptomatology, heterogeneous neuropathology, and robust responses to targeted therapies across the mutational spectrum in ECD patients with neurological involvement, particularly when conventional therapies have failed.
BACKGROUND:Erdheim-Chester disease (ECD) is a rare histiocytic neoplasm characterized by recurrent alterations in the MAPK (mitogen-activating protein kinase) pathway. The existing literature about the neuro-oncological spectrum of ECD is limited. METHODS: We present retrospective clinical, radiographic, pathologic, molecular, and treatment data from 30 patients with ECD neurohistiocytic involvement treated at a tertiary center. RESULTS: Median age was 52 years (range, 7-77), and 20 (67%) patients were male. Presenting symptoms included ataxia in 19 patients (63%), dysarthria in 14 (47%), diabetes insipidus in 12 (40%), cognitive impairment in 10 (33%), and bulbar affect in 9 (30%). Neurosurgical biopsy specimens in 8 patients demonstrated varied morphologic findings often uncharacteristic of typical ECD lesions. Molecular analysis revealed mutations in BRAF (18 patients), MAP2K1 (5), RAS isoforms (2), and 2 fusions involving BRAF and ALK. Conventional therapies (corticosteroids, immunosuppressants, interferon-alpha [IFN-α], cytotoxic chemotherapy) led to partial radiographic response in 8/40 patients (20%) by MRI with no complete responses, partial metabolic response in 4/16 (25%), and complete metabolic response in 1/16 (6%) by 18F-fluorodeoxyglucose (FDG)-PET scan. In comparison, targeted (kinase inhibitor) therapies yielded partial radiographic response in 10/27 (37%) and complete radiographic response in 14/27 (52%) by MRI, and partial metabolic response in 6/25 (24%) and complete metabolic response in 17/25 (68%) by FDG-PET scan. CONCLUSIONS: These data highlight underrecognized symptomatology, heterogeneous neuropathology, and robust responses to targeted therapies across the mutational spectrum in ECDpatients with neurological involvement, particularly when conventional therapies have failed.
Authors: David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga Journal: N Engl J Med Date: 2015-08-20 Impact factor: 91.245
Authors: Elisabeth J Rushing; John Paul Bouffard; Chris J Neal; Kelly Koeller; Jonathan Martin; Metin Ozdemirli; Hernando Mena; James M Ecklund Journal: J Neurosurg Date: 2004-06 Impact factor: 5.115
Authors: Eli L Diamond; Vivek Subbiah; A Craig Lockhart; Jean-Yves Blay; Igor Puzanov; Ian Chau; Noopur S Raje; Jurgen Wolf; Joseph P Erinjeri; Jean Torrisi; Mario Lacouture; Elena Elez; Ferran Martínez-Valle; Benjamin Durham; Maria E Arcila; Gary Ulaner; Omar Abdel-Wahab; Bethany Pitcher; Martina Makrutzki; Todd Riehl; José Baselga; David M Hyman Journal: JAMA Oncol Date: 2018-03-01 Impact factor: 31.777
Authors: Eli L Diamond; Benjamin H Durham; Gary A Ulaner; Esther Drill; Justin Buthorn; Michelle Ki; Lillian Bitner; Hana Cho; Robert J Young; Jasmine H Francis; Raajit Rampal; Mario Lacouture; Lynn A Brody; Neval Ozkaya; Ahmet Dogan; Neal Rosen; Alexia Iasonos; Omar Abdel-Wahab; David M Hyman Journal: Nature Date: 2019-03-13 Impact factor: 49.962
Authors: Saurabh Zanwar; Jithma P Abeykoon; Surendra Dasari; Aishwarya Ravindran; Jason R Young; Aldo A Acosta-Medina; Karen L Rech; Jonathan Schwartz; Aaron Mangold; Allison Rosenthal; N Nora Bennani; Mithun V Shah; Diana Morlote; Gaurav Goyal; Ronald S Go Journal: Blood Cancer J Date: 2022-06-28 Impact factor: 9.812
Authors: Paul G Kemps; Jennifer Picarsic; Benjamin H Durham; Zofia Hélias-Rodzewicz; Laura Hiemcke-Jiwa; Cor van den Bos; Marianne D van de Wetering; Carel J M van Noesel; Jan A M van Laar; Robert M Verdijk; Uta E Flucke; Pancras C W Hogendoorn; F J Sherida H Woei-A-Jin; Raf Sciot; Andreas Beilken; Friedrich Feuerhake; Martin Ebinger; Robert Möhle; Falko Fend; Antje Bornemann; Verena Wiegering; Karen Ernestus; Tina Méry; Olga Gryniewicz-Kwiatkowska; Bozenna Dembowska-Baginska; Dmitry A Evseev; Vsevolod Potapenko; Vadim V Baykov; Stefania Gaspari; Sabrina Rossi; Marco Gessi; Gianpiero Tamburrini; Sébastien Héritier; Jean Donadieu; Jacinthe Bonneau-Lagacherie; Claire Lamaison; Laure Farnault; Sylvie Fraitag; Marie-Laure Jullié; Julien Haroche; Matthew Collin; Jackie Allotey; Majid Madni; Kerry Turner; Susan Picton; Pasquale M Barbaro; Alysa Poulin; Ingrid S Tam; Dina El Demellawy; Brianna Empringham; James A Whitlock; Aditya Raghunathan; Amy A Swanson; Mariko Suchi; Jon M Brandt; Nabeel R Yaseen; Joanna L Weinstein; Irem Eldem; Bryan A Sisk; Vaishnavi Sridhar; Mandy Atkinson; Lucas R Massoth; Jason L Hornick; Sanda Alexandrescu; Kee Kiat Yeo; Kseniya Petrova-Drus; Stephen Z Peeke; Laura S Muñoz-Arcos; Daniel G Leino; David D Grier; Robert Lorsbach; Somak Roy; Ashish R Kumar; Shipra Garg; Nishant Tiwari; Kristian T Schafernak; Michael M Henry; Astrid G S van Halteren; Oussama Abla; Eli L Diamond; Jean-François Emile Journal: Blood Date: 2022-01-13 Impact factor: 22.113
Authors: Ruham Alshiekh Nasany; Anne S Reiner; Jasmine H Francis; Oussama Abla; Katherine S Panageas; Eli L Diamond Journal: Orphanet J Rare Dis Date: 2022-03-02 Impact factor: 4.123
Authors: Paul G Kemps; Konnie M Hebeda; Steven T Pals; Robert M Verdijk; King H Lam; Annette H Bruggink; Heleen S de Lil; Bart Ruiterkamp; Koen de Heer; Jan Am van Laar; Peter Jm Valk; Pim Mutsaers; Mark-David Levin; Pancras Cw Hogendoorn; Astrid Gs van Halteren Journal: J Pathol Clin Res Date: 2020-08-27